72
+5.88%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Nano Holdings
Its shares trade on Tokyo Stock Exchange under the ticker 4571.T. It has been listed since 5 March 2008. In the fiscal year to 31 March 2026, it reported revenue of ¥174.5m and a net loss of ¥943.9m. At that date it held total assets of ¥5.91bn and shareholders' equity of ¥3.57bn.
NanoCarrier Co., Ltd. engages in the research, development, and production of pharmaceuticals using micellar nanoparticles technology. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2008-03-05. The firm develops businesses using the research and development of messenger ribonucleic acid (mRNA) medicine. The products under development are specialized in mRNA medicines. mRNA medicine is a medicine that prevents or treats diseases by administering artificially produced mRNA to the body and allowing the body to discover the protein encoded by the mRNA. Its pipeline includes RUNX1, the mRNA drug pipeline, non-mRNA drug pipeline, Comrex otological liquid 1.5%, NC-6100, TUG1, and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 5 Mar 2008
- Employees
- 17
- Website
- nanomrna.co.jp ↗
Leadership
Pay as last reported
- Mr. Atsushi MatsumuraChairman of the Board
- Mr. Shiro AkinagaPresident, Chief Executive Officer, President of Subsidiary, Representative Director, since 2020
- Mr. Satoru IinoVice Chairman
- Mr. Koji FujimotoChief Financial Officer, Executive Officer, since 2020
- Mr. Norihiko ShiraishiExecutive Officer, Chief Scientific Officer, Manager of mRNA IPG Unit
- Ms. Yuuko OnoderaExecutive Officer, Deputy Chief Director of Main Corporate Unit, Director of Accounting, Director of Research and Development Planning in Main Research and Development Unit
- Mr. Daisuke TakashimaExecutive Officer, Chief Development Officer, Chief Director of Research Development
- Ms. Chieko TsuchiyaExecutive Officer, Director of Corporate Communication
- Mr. Hajime KurozuIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company has a focused research and development in mRNA medicine technology.
- Operates with a small team of 17 full-time employees.
- Has a clear pipeline including RUNX1 and other mRNA drug developments.
Weaknesses
- Limited employee count may restrict operational capacity.
- Reliance on a single technology (mRNA) could pose risks.
- No mention of revenue or financial performance data provided.
Opportunities
- Growing interest in mRNA-based therapies could expand market opportunities.
- Potential for partnerships in biotechnology and pharmaceutical sectors.
- Expanding pipeline with multiple drug candidates may attract investment.
Threats
- Competition in the biotechnology sector could impact market share.
- Regulatory challenges specific to mRNA medicine development.
- Dependence on a single technology may limit adaptability to market changes.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.